Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.
Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Michel C Nussenzweig" Clear advanced filters

  • Alexander D. Gitlin and Michel C. Nussenzweig reflect on the discovery of two lineages of adaptive immune cells, and how it influenced vaccination, cancer therapy and the development of a class of antibody-based drugs.

    • Alexander D. Gitlin
    • Michel C. Nussenzweig
    Comments & Opinion
    Nature
    Volume: 517, P: 139-141

  • Leading COVID-19 vaccine candidates have progressed through laboratory tests at record speed. Two early clinical trials suggest that immunization delivers a favourable immune response and safety profile, but questions remain.

    • Christian Gaebler
    • Michel C. Nussenzweig
    News & Views
    Nature
    Volume: 586, P: 501-502

  • More than 30 years since the AIDS pandemic began, there is still no effective vaccine. But analysis of broadly acting, potent human antibodies obtained from single cells suggests a rational approach to vaccine development. See Article p.469

    • Hugo Mouquet
    • Michel C. Nussenzweig
    News & Views
    Nature
    Volume: 496, P: 441-442

  • Immunologist and cheerleader for dendritic-cell biology.

    • Michel C. Nussenzweig
    • Ira Mellman
    Comments & Opinion
    Nature
    Volume: 478, P: 460